Radiopharm FY26 Loss Widens 50% to A$57M; Cash Down to A$4.1M, Going-Concern Warning Ahead
RADX is trading near its 52-week low of $2.044 (14% above the low).
Summary
Radiopharm Theranostics reported a 50% wider FY2026 loss of A$56.95M and cash of just A$4.14M, with a going-concern warning expected in the audited financials due by end of September.
Key Events · Earnings and Guidance · RADX
-
FY26 Loss Widens 50% to A$56.95M
Net loss attributable to owners rose 50.3% to A$55.15M (total loss A$56.95M), driven by R&D expenses nearly doubling to A$49.96M from A$27.52M.
-
Cash Collapses to A$4.14M
Cash and cash equivalents fell from A$29.12M to A$4.14M at 30 June 2026, with net cash used in operating activities of A$52.78M for the year.
-
Going-Concern Uncertainty Expected
Audited financial statements due by 30 September 2026 are expected to include a material uncertainty related to going concern.
-
Negative Net Tangible Assets
Net tangible assets per ordinary security deteriorated to negative A$0.0045 from negative A$0.0016 a year earlier.
Analysis · RADX · Life Sciences
Radiopharm's preliminary FY2026 results reveal a sharply deteriorating financial position. The net loss widened 50.3% to A$56.95 million, driven by R&D spending that nearly doubled to A$49.96 million. Cash collapsed from A$29.1 million to A$4.14 million over the year, and the company now expects its audited financial statements to carry a material uncertainty related to going concern. Net tangible assets per share are negative. Against that backdrop, the company has already launched a A$18.5 million capital raise (institutional offer plus share purchase plan) and has an EGM scheduled for 11 September 2026 to approve the remaining components. The runway is extremely thin — roughly one quarter based on the Q2 cash burn — so the outcome of the capital raise and the EGM vote are now existential for the company.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.2% of the 374 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RADX was trading at $2.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31.2M. The 52-week trading range was $2.04 to $16.25. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.